Abbott launches study assessing benefits of CardioMEMS HF System

Abbott has announced the launch of its landmark GUIDE-HF clinical trial, which will assess the benefits of the CardioMEMS HF System.

The trial will study whether CardioMEMS can improve survival and quality of life for people living with heart failure, with 3,600 patients to be enrolled across 140 North American hospitals.

GUIDE-HF trial is designed to build on the clinical experience generated from the CHAMPION trial, offering additional clinical evidence to further expand coverage for this innovative technology.

CardioMEMS HF has already been proven to significantly reduce heart failure hospital admissions and improve the quality of life for people living with this condition.

Dr Philip Adamson, divisional vice-president and medical director of Abbott's heart failure business, said: "The CardioMEMS HF System is a first-of-its-kind approach to redefine heart failure management. The GUIDE-HF study sets out to make this technology available to an expanded group of people who could benefit from it."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.